US Market for Tinea Pedis (Athlete's Foot) Drugs to Reach $555 million by 2015, According to a New Report by Global Industry Analysts, Inc.
GIA announces the release of a comprehensive US market report on Tinea Pedis (Athlete's Foot). The US market for Tinea Pedis medications is projected to reach $555 million by 2015. Due to the dominance of generics, the market for tinea pedis treatment is currently sluggish. However, the market exhibits highly attractive commercial opportunity for novel drugs and formulation technologies under development that offer rapid penetration and are therapeutically more effective. Besides this, with the increase in aging population and diabetes patients, foot problems are also on rise, thereby generating a huge opportunity for foot care products manufacturers.
San Jose, California (Vocus) August 15, 2010
Skin conditions represent one of the most common health-related problems having a burdensome impact on the well-being of individuals. Although, majority of the skin diseases are not life threatening, yet several of such conditions hamper quality of life and result in considerable healthcare expenses to the nation. About 70% of the population in the world is believed to experience a cutaneous mycotic infection at some point in their lives. Tinea pedis or athlete’s foot, the most prevalent mycotic infection worldwide, is caused by a dermatophyte in over 90% of the patients. This highly contagious disease results in itching, peeling, and scaling of the skin that can be generally treated at home using anti-fungal medications. In the US, Athlete’s foot is the second most common skin complaint, with about 45% of the people suffering periodically for 10 years or more. The problem is widespread with a high rate of recurrence and could lead to serious complications in individuals at risk. Over 70% of the population in the US suffer from tinea pedis at some time in their lives, while about 33% of such patients are estimated to contract toenail infections too. Besides age, diabetes also acts as a major risk factor, as diabetics are 50% more prone to a fungal infection as compared to non-diabetics.
With demanding and time consuming clinical trials thwarting the timely introduction of drugs, the prescription market for tinea pedis treatment is primarily dominated by generics, as stated by the new market research report on Tinea Pedis The anti fungal market has been less dynamic in recent years as no novel prescription anti-fungal agent has been launched since the past 5-6 years. Major pharmaceutical companies, in the absence of any patent protection, face stiff competition from generics, hence suffering decline in sales. Moreover as many of the existing over-the-counter medications are becoming less effective against various fungi strains, there exists wide opportunity for novel treatments. As most of the currently approved products for topical treatment of athlete’s foot have moderate efficacy and require long duration therapy extending to a month, current focus is towards development of more effective therapies that require half the treatment time. Players are also focusing on new formulation technologies that deliver the antifungal agent in large amounts and for a prolonged period into the skin, making one-shot treatment feasible.
Key players profiled in the study include Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson,
Kaken Pharmaceutical Co., Merck & Co. Inc., Nitric BioTherapeutics, Novartis AG, Sanofi-Aventis, Stiefel Laboratories, and Topica Pharmaceuticals.
The report titled “Tinea Pedis (Athlete's Foot): A US Market Report” announced by Global Industry Analysts Inc., provides a comprehensive review of current market trends, key growth drivers, recent industry activity, research and development initiatives and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for the US market for the years 2006 through 2015.
For more details about this comprehensive market research report, please visit – http://www. strategyr. com/Tinea_Pedis_Athletes_Foot_Market_Report. asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Web Site http://www. StrategyR. com/
###
